南宫NG·28(中国)相信品牌力量

Shanghai, China – Hercules™-T Low Profile Stent-Graft ("HT-LP"), in-house developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was recently included in the 2017 Shanghai Innovative Product Recommendation List ("Recommendation List") according to an announcement recently released by Shanghai Municipal Commission of Economy and Informatization. Such honor is expected to benefit the commercialization and industrialization of HT-LP.

The Recommendation List is designed to facilitate the implantation of Shanghai government's innovation-driven strategies to build a technological innovation center in the city. The Recommendation List is expected to provide references to decision makers of government purchasing to encourage and facilitate the development and application of innovative products. The product selected into this year’s list were also included in the government purchasing project system for their major innovation, independent intellectual property, great potential for economic benefits and promising market prospect. This year, only 66 products were included in the Recommendation List.

HT-LP is built on the success of Hercules® Thoracic Stent-Graft System. It is designed for the endovascular treatment of descending thoracic aortic disease. HT-LP has significant advantages in outer diameter and cross arch ability compared to similar products on the market. It is the first thoracic aortic aneurysm ("TAA") stent to have low profile delivery system with 18F outer diameter, the lowest among aortic stents in the world, which would benefit patients with narrow introducing femoral artery, mostly Asian female patients. Its soft inner sleeves are made of PET, which makes it easier for the stent to cross the aortic arch. The rear release mechanism of bare stent leads to more precise and stable positioning and deployment. The product offers 0-10mm taper availability, in accordance with the pathological features of aortic dissection. The height-mutative main body stent improves the flexibility of the whole stent.

MicroPort® Endovascular will continue to build a technology innovation system, actively carry out the transformation of scientific research achievement, and enhance independent innovation, integrated innovation and cooperative innovation, so as to offer more safe, effective, high quality and affordable high-end medical devices to patients and help drive the development of Shanghai's innovative technology.